[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06887192":3,"trial-entities:NCT06887192":425,"trial-summary:NCT06887192":429},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":37,"primary_purpose":38,"phases":39,"enrollment_info":41,"interventions":44,"primary_outcomes":54,"secondary_outcomes":59,"sex":66,"minimum_age":67,"maximum_age":68,"healthy_volunteers":69,"eligibility_criteria":70,"std_ages":74,"locations":77,"central_contacts":414,"overall_officials":420,"references":423,"see_also_links":424},"NCT06887192","ML-007C-MA-221","A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis","RECRUITING","2027-12","2026-05","2026-08-27","2025-08-15","MapLight Therapeutics","INDUSTRY",true,"ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).\n\nThe primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.",null,[19],"Psychosis Associated With Alzheimer's Disease",[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36],"Alzheimer Disease","Brain Diseases","Central Nervous System Diseases","Delusions","Dementia","Hallucinations","Mental Disorders","Nervous System Diseases","Neurocognitive Disorders","Neurodegenerative Diseases","Psychotic Disorders","Schizophrenia Spectrum and Other Psychotic Disorders","Tauopathies","Muscarinic Antagonists","Muscarinic Agonists","Cholinergic Agents","INTERVENTIONAL","TREATMENT",[40],"PHASE2",{"count":42,"type":43},300,"ESTIMATED",[45,50],{"type":46,"name":47,"description":48,"armGroupLabels":49},"DRUG","ML-007C-MA","ML-007C-MA dosed as 105\u002F1.5 mg BID, or 210\u002F3 mg BID",[47],{"type":46,"name":51,"description":52,"armGroupLabels":53},"Placebo","Placebo Tablets",[51],[55],{"measure":56,"description":57,"timeFrame":58},"Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score","NPI-C H+D scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.","Baseline and End of Treatment (7 weeks)",[60,63],{"measure":61,"description":62,"timeFrame":58},"Change from Baseline to End of Treatment in the Clinical Global Impressions-Severity (CGI-S) hallucinations and delusions domain-specific score","The CGI-S scale is a clinician-rated, 7-point scale that is designed to rate the severity of the participant's hallucinations and delusions using the investigator's judgment and past experience with participants who have Alzheimer's disease psychosis. Higher scores on this scale indicate worse outcomes.",{"measure":64,"description":65,"timeFrame":58},"Change from Baseline to End of Treatment in the Neuropsychiatric Inventory - Clinician Agitation and Aggression (NPI-C A+A) score in participants who have a CGI-S agitation\u002Faggression domain-specific score of ≥4 at Baseline","NPI-C A+A scale includes 2 domains from the NPI-C scale, namely, agitation and aggression. These 2 domains include the following number of items to be rated by the clinician: Agitation, 13 items (maximum score = 39), and Aggression, 8 items (maximum score = 24). The maximum score for the NPI-C A+A scale is 63. Higher scores on this scale indicate more severe symptoms of agitation and aggression.","ALL","55 Years","90 Years",false,{"inclusion":71,"exclusion":72,"raw_text":73},[],[],"Key Inclusion Criteria:\n\n1. Willing and able to provide written informed consent, or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:\n\n   1. The participant's LAR must provide written informed consent AND\n   2. The participant will provide informed assent.\n2. Meets clinical criteria for Possible AD or Probable AD.\n3. Presence of psychotic symptoms (meeting International Psychogeriatric Association criteria) (Cummings 2020) for at least 2 months before Screening.\n4. Has resided at the same home, residential assisted living, or nursing home facility for a minimum of 6 weeks before Screening.\n5. Has a designated care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug.\n6. Has a NPI-C H+D score of ≥ 6 AND meet at least 1 of the following criteria:\n\n   1. Moderate to severe delusions, defined as NPI-C Delusions domain score of ≥ 2 on at least 2 of the 8 items OR\n   2. Moderate to severe hallucinations, defined as NPI-C Hallucinations domain score of ≥ 2 on at least 2 of the 7 items.\n7. Has a (CGI)-S hallucinations and delusions domain-specific score ≥4\n8. Has an Mini-mental State Examination (MMSE) score of 6 to 26, inclusive.\n\nKey Exclusion Criteria:\n\n1. Under the care of hospice, bed-bound, or receiving end-of-life palliative care.\n2. Psychotic symptoms that are primarily attributable to substance abuse or a medical, neurological or psychiatric condition other than Alzheimer's disease.\n3. Evidence of a CNS disorder other than Alzheimer's disease that is the primary cause of, or a significant contributor to the participant's dementia.\n4. Moderate or severe major depressive episode within 3 months of Screening, according to DSM-5 criteria.\n5. Has an elevated risk of suicidal behavior\n6. Has had an amyloid PET brain scan or CSF Alzheimer's disease biomarker test in the past 3 years with results inconsistent with a diagnosis of AD.\n7. Evidence of a clinically significant and\u002For unstable medical condition that, in the opinion of the investigator or medical monitor, could substantially impair cognition, compromise participant safety, interfere with the participant's ability to comply with study procedures or substantially impair the evaluation of efficacy or safety assessments.\n8. Gastric retention, urinary retention or narrow-angle (angle-closure) glaucoma\n9. Meets or has met DSM-5 criteria for alcohol or substance use disorder within the past 12 months (excluding caffeine and nicotine).\n10. Has previously participated in any clinical study with ML-007 or ML-007C-MA.\n11. Has developed an allergy or other intolerance to ML-007C-MA, its active ingredients or their excipients.\n12. Received or may have received an investigational drug, biological product or device within 90 days before Baseline (or 6 months for investigational Alzheimer's disease-modifying therapies).",[75,76],"ADULT","OLDER_ADULT",[78,87,93,99,106,112,118,124,130,137,144,150,156,162,167,170,173,176,182,185,191,197,203,209,216,222,229,236,243,249,256,263,269,272,279,287,290,297,300,309,315,321,328,335,341,348,355,358,365,372,380,387,394,401,408],{"facility":79,"status":8,"city":80,"state":81,"zip":82,"country":83,"geoPoint":84},"Clinical Site","Phoenix","Arizona","85004","United States",{"lat":85,"lon":86},33.44838,-112.07404,{"facility":79,"status":8,"city":88,"state":81,"zip":89,"country":83,"geoPoint":90},"Scottsdale","85253",{"lat":91,"lon":92},33.50921,-111.89903,{"facility":79,"status":8,"city":94,"state":81,"zip":95,"country":83,"geoPoint":96},"Tucson","85704",{"lat":97,"lon":98},32.22174,-110.92648,{"facility":79,"status":8,"city":100,"state":101,"zip":102,"country":83,"geoPoint":103},"Anaheim","California","92805",{"lat":104,"lon":105},33.83529,-117.9145,{"facility":79,"status":8,"city":107,"state":101,"zip":108,"country":83,"geoPoint":109},"Long Beach","90807",{"lat":110,"lon":111},33.76696,-118.18923,{"facility":79,"status":8,"city":113,"state":101,"zip":114,"country":83,"geoPoint":115},"Murrieta","92562",{"lat":116,"lon":117},33.55391,-117.21392,{"facility":79,"status":8,"city":119,"state":101,"zip":120,"country":83,"geoPoint":121},"Orange","92866",{"lat":122,"lon":123},33.78779,-117.85311,{"facility":79,"status":8,"city":125,"state":101,"zip":126,"country":83,"geoPoint":127},"San Diego","92123",{"lat":128,"lon":129},32.71571,-117.16472,{"facility":79,"status":8,"city":131,"state":132,"zip":133,"country":83,"geoPoint":134},"Denver","Colorado","80218",{"lat":135,"lon":136},39.73915,-104.9847,{"facility":79,"status":8,"city":138,"state":139,"zip":140,"country":83,"geoPoint":141},"Boca Raton","Florida","33428",{"lat":142,"lon":143},26.35869,-80.0831,{"facility":79,"status":8,"city":145,"state":139,"zip":146,"country":83,"geoPoint":147},"Deerfield Beach","33442",{"lat":148,"lon":149},26.31841,-80.09977,{"facility":79,"status":8,"city":151,"state":139,"zip":152,"country":83,"geoPoint":153},"Doral","33122",{"lat":154,"lon":155},25.81954,-80.35533,{"facility":79,"status":8,"city":157,"state":139,"zip":158,"country":83,"geoPoint":159},"Homestead","33033",{"lat":160,"lon":161},25.46872,-80.47756,{"facility":79,"status":8,"city":163,"state":139,"zip":152,"country":83,"geoPoint":164},"Miami",{"lat":165,"lon":166},25.77427,-80.19366,{"facility":79,"status":8,"city":163,"state":139,"zip":168,"country":83,"geoPoint":169},"33155",{"lat":165,"lon":166},{"facility":79,"status":8,"city":163,"state":139,"zip":171,"country":83,"geoPoint":172},"33173",{"lat":165,"lon":166},{"facility":79,"status":8,"city":163,"state":139,"zip":174,"country":83,"geoPoint":175},"33186",{"lat":165,"lon":166},{"facility":79,"status":8,"city":177,"state":139,"zip":178,"country":83,"geoPoint":179},"Miami Gardens","33014",{"lat":180,"lon":181},25.94204,-80.2456,{"facility":79,"status":8,"city":177,"state":139,"zip":183,"country":83,"geoPoint":184},"33104",{"lat":180,"lon":181},{"facility":79,"status":8,"city":186,"state":139,"zip":187,"country":83,"geoPoint":188},"Naples","34105",{"lat":189,"lon":190},26.14234,-81.79596,{"facility":79,"status":8,"city":192,"state":139,"zip":193,"country":83,"geoPoint":194},"Orlando","32807",{"lat":195,"lon":196},28.53834,-81.37924,{"facility":79,"status":8,"city":198,"state":139,"zip":199,"country":83,"geoPoint":200},"Tampa","33629",{"lat":201,"lon":202},27.94752,-82.45843,{"facility":79,"status":8,"city":204,"state":139,"zip":205,"country":83,"geoPoint":206},"West Palm Beach","33407",{"lat":207,"lon":208},26.71534,-80.05337,{"facility":79,"status":8,"city":210,"state":211,"zip":212,"country":83,"geoPoint":213},"Augusta","Georgia","30912",{"lat":214,"lon":215},33.47097,-81.97484,{"facility":79,"status":8,"city":217,"state":211,"zip":218,"country":83,"geoPoint":219},"Snellville","30078",{"lat":220,"lon":221},33.85733,-84.01991,{"facility":79,"status":8,"city":223,"state":224,"zip":225,"country":83,"geoPoint":226},"Las Vegas","Nevada","89121",{"lat":227,"lon":228},36.17497,-115.13722,{"facility":79,"status":8,"city":230,"state":231,"zip":232,"country":83,"geoPoint":233},"West Long Branch","New Jersey","07764",{"lat":234,"lon":235},40.29039,-74.01764,{"facility":79,"status":8,"city":237,"state":238,"zip":239,"country":83,"geoPoint":240},"Dayton","Ohio","45459",{"lat":241,"lon":242},39.75895,-84.19161,{"facility":79,"status":8,"city":244,"state":238,"zip":245,"country":83,"geoPoint":246},"Independence","44131",{"lat":247,"lon":248},41.36866,-81.6379,{"facility":79,"status":8,"city":250,"state":251,"zip":252,"country":83,"geoPoint":253},"Tigard","Oregon","97223",{"lat":254,"lon":255},45.43123,-122.77149,{"facility":79,"status":8,"city":257,"state":258,"zip":259,"country":83,"geoPoint":260},"Austin","Texas","78757",{"lat":261,"lon":262},30.26715,-97.74306,{"facility":79,"status":8,"city":264,"state":258,"zip":265,"country":83,"geoPoint":266},"McKinney","75071",{"lat":267,"lon":268},33.19762,-96.61527,{"facility":79,"status":8,"city":270,"state":258,"zip":271,"country":83},"Sugarland","77478",{"facility":79,"status":8,"city":273,"state":274,"zip":275,"country":83,"geoPoint":276},"Bellevue","Washington","98007",{"lat":277,"lon":278},47.61038,-122.20068,{"facility":79,"status":8,"city":280,"state":281,"zip":282,"country":283,"geoPoint":284},"Córdoba","Córdoba Province","X5009BIN","Argentina",{"lat":285,"lon":286},-31.40648,-64.18853,{"facility":79,"status":8,"city":280,"zip":288,"country":283,"geoPoint":289},"X5004AOA",{"lat":285,"lon":286},{"facility":79,"status":8,"city":291,"state":291,"zip":292,"country":293,"geoPoint":294},"Pernik","2304","Bulgaria",{"lat":295,"lon":296},42.59671,23.03318,{"facility":79,"status":8,"city":298,"state":298,"zip":299,"country":293},"Sofia","1408",{"facility":79,"status":301,"city":302,"state":303,"zip":304,"country":305,"geoPoint":306},"NOT_YET_RECRUITING","Brampton","Ontario","L6W 2Z8","Canada",{"lat":307,"lon":308},43.68341,-79.76633,{"facility":79,"status":8,"city":310,"state":303,"zip":311,"country":305,"geoPoint":312},"London","N6A 5W9",{"lat":313,"lon":314},42.98339,-81.23304,{"facility":79,"status":8,"city":316,"state":303,"zip":317,"country":305,"geoPoint":318},"Toronto","M4N 3M5",{"lat":319,"lon":320},43.70643,-79.39864,{"facility":79,"status":8,"city":322,"state":323,"zip":324,"country":305,"geoPoint":325},"Lévis","Quebec","G6V 0C9",{"lat":326,"lon":327},46.80326,-71.17793,{"facility":79,"status":8,"city":329,"zip":330,"country":331,"geoPoint":332},"Choceň","565 01","Czechia",{"lat":333,"lon":334},50.00161,16.22303,{"facility":79,"status":8,"city":336,"zip":337,"country":331,"geoPoint":338},"Prague","150 00",{"lat":339,"lon":340},50.08804,14.42076,{"facility":79,"status":8,"city":342,"zip":343,"country":344,"geoPoint":345},"Toulouse","31059","France",{"lat":346,"lon":347},43.60426,1.44367,{"facility":79,"status":8,"city":349,"zip":350,"country":351,"geoPoint":352},"Pécs","7623","Hungary",{"lat":353,"lon":354},46.07617,18.22814,{"facility":79,"status":8,"city":349,"zip":356,"country":351,"geoPoint":357},"7633",{"lat":353,"lon":354},{"facility":79,"status":8,"city":359,"zip":360,"country":361,"geoPoint":362},"Roma","00128","Italy",{"lat":363,"lon":364},44.99364,11.10642,{"facility":79,"status":8,"city":366,"zip":367,"country":368,"geoPoint":369},"Plewiska","62-064","Poland",{"lat":370,"lon":371},52.36706,16.80985,{"facility":79,"status":8,"city":373,"state":374,"zip":375,"country":376,"geoPoint":377},"Torres Vedras","Lisbon District","2560-280","Portugal",{"lat":378,"lon":379},39.09109,-9.2586,{"facility":79,"status":8,"city":381,"zip":382,"country":383,"geoPoint":384},"Bucharest","041914","Romania",{"lat":385,"lon":386},44.43225,26.10626,{"facility":79,"status":8,"city":388,"zip":389,"country":390,"geoPoint":391},"Kragujevac","34000","Serbia",{"lat":392,"lon":393},44.01667,20.91667,{"facility":79,"status":8,"city":395,"zip":396,"country":397,"geoPoint":398},"Vranov nad Topľou","093 01","Slovakia",{"lat":399,"lon":400},48.88836,21.68479,{"facility":79,"status":8,"city":402,"zip":403,"country":404,"geoPoint":405},"Daegu","41404","South Korea",{"lat":406,"lon":407},35.87028,128.59111,{"facility":79,"status":8,"city":409,"zip":410,"country":404,"geoPoint":411},"Incheon","21565",{"lat":412,"lon":413},37.45646,126.70515,[415],{"name":416,"role":417,"phone":418,"email":419},"Clinical Trials Contact Center","CONTACT","+1 650 839 4380","ML-007C-MA-ADP@maplightrx.com",[421],{"name":13,"affiliation":13,"role":422},"STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":426,"biomarkers":428},[427],"Alzheimer's Disease",[],{"nct_id":4,"found":15,"summary":430,"prompt_version":440},{"design":431,"status":432,"heading":433,"summary":434,"follow_up":435,"word_count":436,"commitments":437,"compensation":438,"drugs_mentioned":439},"This is a Phase 2, randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either ML-007C-MA or a placebo, and neither you nor your doctor will know which you are receiving. The study plans to enroll about 300 participants.","completed","ML-007C-MA for Alzheimer's Disease Psychosis","This study is testing a drug called ML-007C-MA to see if it can help reduce hallucinations and delusions in people with Alzheimer's disease psychosis (ADP). Researchers will compare ML-007C-MA to a placebo (an inactive pill that looks like the study drug). We are looking for about 300 participants, aged 55 to 90, who have been diagnosed with possible or probable Alzheimer's disease and are experiencing hallucinations and delusions. The main goal is to see if ML-007C-MA improves these symptoms over 7 weeks, as measured by a specific rating scale called the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score. The study status is currently unclear.","The primary outcome is measured at the end of treatment, which is 7 weeks.",105,"Not specified in the trial record.","Not stated in the trial record.",[47,51],"v2"]